Study of Baicalin toward COVID-19 Treatment: In silico Target Analysis and in vitro Inhibitory Effects on SARS-CoV-2 Proteases

Chingju Lin^a Fuu-Jen Tsai^{b, c, d} Yuan-Man Hsu^e Tsung-Jung Ho^{f, g, h}
Guo-Kai Wangⁱ Yu-Jen Chiu^{j, k, l} Hai-Anh Ha^{m, n} Jai-Sing Yang^o

^aDepartment of Physiology, China Medical University, Taichung, Taiwan; ^bSchool of Chinese Medicine, China Medical University, Taichung, Taiwan; ^cDepartment of Medical Research, Human Genetics Center, China Medical University Hospital 404, Taichung, Taiwan; ^dDepartment of Medical Genetics, China Medical University Hospital, Taichung, Taiwan; ^eDepartment of Biological Science and Technology, China Medical University, Taichung, Taiwan; ^fDepartment of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan; ^gIntegration Center of Traditional Chinese and Modern Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan; ^hSchool of Post-Baccalaureate Chinese Medicine, College of Medicine, Tzu Chi University, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan; ⁱSchool of Pharmacy, Anhui University of Chinese Medicine, Anhui Province Key Laboratory of Research & Development of Chinese Medicine, Hefei, China; ^jDivision of Reconstructive and Plastic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; ^kDepartment of Surgery, School of Medicine, National Yang Ming University, Taipei, Taiwan; ^lInstitute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan; ^mSchool of Pharmacy, China Medical University, Taichung, Taiwan; ⁿFaculty of Pharmacy, Duy Tan University, Da Nang, Vietnam; ^oDepartment of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan

Keywords

Baicalin · Coronavirus disease-19 · SARS-CoV-2 · 3-Chymotrypsin-like cysteine protease · Papain-like protease

Abstract

Negative impacts of COVID-19 on human health and economic and social activities urge scientists to develop effective treatments. Baicalin is a natural flavonoid, extracted from a traditional medicinal plant, previously reported with anti-inflammatory activity. In this study, we used pharmacophore fitting and molecular docking to screen and determine docking patterns and the binding affinity of baicalin on 3 major targets of SARS-CoV-2 (3-chymotrypsin-like cysteine

protease [3CLpro], papain-like protease [PLpro], and RNA-dependent RNA polymerase). The obtained data revealed that baicalin has high pharmacophore fitting on 3CLpro and predicted good binding affinity on PLpro. Moreover, using the enzymatic assay, we examined the inhibitory effect of baicalin in vitro on the screened enzymes. Baicalin also exhibits inhibitory effect on these proteases in vitro. Additionally, we performed pharmacophore-based screening of baicalin on human targets and conducted pathway analysis to explore the potential cytoprotective effects of baicalin in the host cell that may be beneficial for COVID-19 treatment. The result suggested that baicalin has multiple targets in human cell that may induce multiple pharmacological effects. The result of pathway analysis implied that these targets may be associated with baicalin-induced bioactivities that are in-

volved with signals of pro-inflammation factors, such as cytokine and chemokine. Taken together with supportive data from the literature, the bioactivities of baicalin may be beneficial for COVID-19 treatment by reducing cytokine-induced acute inflammation. In conclusion, baicalin is potentially a good candidate for developing new therapeutic to treat COVID-19.

© 2021 The Author(s)

Published by S. Karger AG, Basel

Introduction

COVID-19 has been identified as a pandemic since March 2020; since then, billions of people around the world have suffered negative impacts of COVID-19 on human health as well as socioeconomic activities [1, 2]. In response to the pandemic, preventive measures and clinical care are the main front-line battles for reducing morbidity and mortality. Recent vaccination roll-out in a number of countries is the most efficient measure for COVID-19 prevention. However, concerns are still rising about the emergence of new virus variants, uneven supply of vaccines, and little improvement in treatment discovery [3, 4]. Since COVID-19 is a new disease, more research is urgently needed to find an effective treatment to cope with this public health crisis.

SARS-CoV-2, a single-strand RNA coronavirus is the pathogen of COVID-19 [5]. Based on the accumulated studies of pathogenesis of coronaviruses family, several molecular targets were selected for discovering therapeutics against SARS-CoV-2, namely, 3-chymotrypsin-like cysteine protease (3CLpro), papain-like protease (PLpro), and RNA-dependent RNA polymerase (RDRP) [6–8]. As these enzymatic proteins are crucial for virus replication, inhibiting these targets may reduce virus load, thereby inducing an antiviral effect [9]. In addition, the discovery of drugs intended to treat severe symptoms of COVID-19 is of interest to laboratories [6]. The progression of COVID-19 is associated with acute inflammation and immune response that may cause hyper-inflammatory syndrome, referred as the “cytokine storm” (CS) [10]. The molecular mechanism behind a CS is known as the excessive releasing of pro-inflammatory molecules, such as IL-1, IL-6, and TNF- α [11]. Therefore, the CS can be dismissed by inhibiting the cytokine amplification or blocking cytokine-induced signaling cascade inside the host cell [12].

Baicalin is a bioactive natural compound, isolated from the medicinal plant *Scutellaria baicalensis* (SB), a commonly used plant in traditional Chinese medicine

[13]. Extract of SB has been reported with anti-inflammation [14, 15], antioxidant [13, 16], or antiviral [17, 18] activities that possibly conferred by its major chemical compositions, such as baicalin and baicalein. Recently, SB and several herbal formulas comprising SB were suggested as potential therapeutics to treat COVID-19 with supportive data provided from in silico approaches or system pharmacological studies [7, 19–22]. Baicalin is known to be responsible for the major biological effects of SB and exhibits anti-inflammatory and antiviral effects with low cytotoxicity [23–25]. Baicalin is the main composition of Flavocoxid, an approved medical food, which is classified as generally recognized as safe by regulatory requirement. A recent repaper reported that, Flavocoxid has low risk and fewer side effects than nonsteroidal anti-inflammatory drugs [26]. Recent reviews mentioned baicalin as a potential compound to develop as COVID-19 therapeutic [21, 27, 28]. However, in order to get closer to the drug development, more evidence and insight is needed about its possible effects on the molecular targets toward COVID-19 treatment.

In this study, we computationally screened and determined potential binding patterns of baicalin on 3 major targets of SARS-CoV-2 (3CLpro, PLpro, and RDRP) and examined the inhibitory effect of baicalin in vitro on the screened enzymes. Furthermore, we performed pharmacophore-based screening of baicalin on human targets and conducted pathway analysis to explore the potential cytoprotective effects of baicalin in the host cell that may also be beneficial for COVID-19 treatment.

Material and Methods

Structure Preparation for in silico studies

The structures of 3CLpro (code: 6W63), PLpro (code: 6WX4), and RDRP (code: 7BV2) of SARS-CoV-2 were obtained from the Protein Data Bank (rcsb.org) [29]. The protein preparation steps, including fixing the common structure problems and applying protonation status at pH 7.4 were processed before docking using integrated tools of BIOVIA, Dassault Systèmes, Discovery Studio 2020, San Diego, CA, USA: Dassault Systèmes, 2020. The chemical features of baicalin was sketched using BIOVIA Draw, followed by the preparation for generating the appropriate protonated isomers and tautomers at pH 7.4 as described previously [28].

In silico Target Screening of Baicalin for SARS-CoV-2 by Pharmacophore Models

Pharmacophore models for molecule interactions were created according to the complexities of the prepared proteins and their in situ ligands as previously described [28]. Each model was also confirmed with the known inhibitors [29–31]. The sensitivity of the pharmacophore model for 3CLpro was 0.73913 (true-positive/to-

tal active: 17/23), while the sensitivities of the pharmacophore model for PLpro and RDRP were 0.5 (true-positive/total active: 1/2), and 0.75 (true-positive/total active: 3/4), respectively. Pharmacophore mapping was conducted using the provided tool of DS 2020 system on 3CLpro, PLpro, and RDRP. The pharmacophore fit value of each ligand in the target was analyzed from the previous pharmacophore mapping result, using the integrated “Ligand Profiler” function of the software system.

Molecular Docking for Baicalin on 3CLpro, PLpro, and RDRP

The baicalin-binding sites on 3CLpro, PLpro, and RDRP of SARS-CoV-2 were identified according to the native co-crystal ligand of the download PDB model. The docking optimization module, CDOCKER protocol embedded in DS 2020 system, was used for the docking process as previously described [28]. To check the accuracy of the docking algorithm, the native inhibitory ligand was used for re-docking and calculating root mean square deviation of the top docking poses to the co-crystallized ligand. The result is presented in online supplementary Table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000519564).

The 3-dimensional (3D) structure of baicalin was downloaded from the PubChem database. After energy minimization, baicalin was docked into 3CLpro, PLpro, or RDRP. The docking result of each target was ranked by the “CDOCKER energy” value to identify the most potential binding pose (lowest binding energy). Docking results were then scored by LigScore1 using the integrated tool “Score Ligand Poses” to obtain the final docking score value. The binding pattern and ligand-receptor interactions were analyzed visually in 3D view and drawn into 2-dimensional diagram as the final result.

Enzymatic Activity and Inhibition Assays

The enzyme activity assays was performed as described previously [32]. Briefly, the protease activity of 3CLpro of SARS-CoV-2 virus was measured by a continuous kinetic assay, with the substrate MCA-AVLQSGFR-Lys (Dnp)-Lys-NH₂ (GL Biochem, Shanghai), using wavelengths of 320 nm and 405 nm for excitation and emission, respectively. Similarly, the protease activity of PLpro of SARS-CoV-2 virus was also measured with the substrate Ubiquitin-AMC.

Pathway Analysis

KEGG pathway analysis (accessible at www.kegg.jp) was used in this study, following the previous guidelines [33]. From the pharmacophore fitting result, with possible targets of baicalin in human cell, and the associated KEGG-IDs were collected and submitted into the KEGG Mapper Web page as a single gene list. The mapping process was performed through the Web interface. The default target pathway database was applied to perform the analysis. Based on the integrated algorithm of KEGG, a list of relevant pathways was then generated by the KEGG system. Results of pathways were annotated with KEGG Orthology identifiers as set by default and shown in the pathway tab by the Web-based system for an on-site view and download for further analysis.

Statistical Analysis

For each in vitro study, 3 independent experiments were conducted. Statistical analysis was performed using 1-way ANOVA followed by Dunnett's post hoc test. *** $p < 0.001$ versus untreated control.

Fig. 1. Chemical structure of baicalin.

Results

In silico Target Analysis of Baicalin with 3CLpro, PLpro, and RDRP

The flavonoids class has been regarded as a promising therapeutic strategy against SARS-CoV-2 infection due to its wide spectrum of biological properties, including antioxidant, anti-inflammatory, and antiviral activities. We examined whether baicalin (molecular formula: C₂₁H₁₈O₁₁, Fig. 1), one of the major flavonoids in the traditional Chinese medicinal herb “Huang qin” also exerts an antiviral activity against SARS-CoV-2 infection. The flow diagram illustrating the research design is shown in Figure 2. After screening 3 possible targets of baicalin for SARS-CoV-2, the in silico assay was performed to determine the binding affinity between baicalin and its potential targets, followed by in vitro protease activity assays. We used pharmacophore models in PharmaDB to determine binding affinities of baicalin plus 3 other positive-control antiviral drugs (remdesivir and lopinavir and ritonavir) to 3CLpro, PLpro, and RDRP of SARS-CoV-2. Among antiviral drugs, remdesivir has been shown to inhibit RDRP, while lopinavir and ritonavir suppress the main protease protein 3CLpro polyprotein of SARS-CoV-2 [9, 34]. The in silico assay results in Table 1 suggested a higher pharmacophore fit value of baicalin (fitting value: 0.726) on 3CLpro than that of lopinavir (0.608) and ritonavir (0.654). However, the docking score result showed a lower score for baicalin (LigScore: 4.47)

Fig. 2. Experimental design of the current study to assess the effect of baicalin against a SARS-CoV-2 infection in silico study. Details are discussed in the text. RDRP, RNA-dependent RNA polymerase; PLpro, papain-like protease; 3CLpro, 3-chymotrypsin-like cysteine protease.

Table 1. The pharmacophore fitting and LigScore results of baicalin and antiviral agents on 3CLpro, PLpro, and RDRP of SARS-CoV-2

Compound name	3CLpro		PLpro		RDRP	
	fitting value	LigScore	fitting value	LigScore	fitting value	LigScore
Remdesivir	–	–	–	–	0.730	6.62
Lopinavir	0.608	6.59	–	–	–	–
Ritonavir	0.654	5.98	–	–	–	–
Baicalin	0.726	4.47	0.573	5.64	0.453	6.49

3CLpro, 3-chymotrypsin-like cysteine protease; PLpro, papain-like protease; RDRP, RNA-dependent RNA polymerase.

than that of lopinavir (6.59) and ritonavir (5.98). On the PLpro target, baicalin demonstrated more promising data with a pharmacophore fitting value (0.573) greater than 0.5 and a LigScore value (5.64) >5. In addition, the in silico screening result on RDRP of baicalin showed both pharmacophore fitting (0.453) and LigScore (6.49) lower than those of remdesivir (0.730 and 6.62, respectively).

Binding patterns of baicalin on the selected targets were then analyzed from the obtained molecular docking result. 3D and 2-dimensional ligand interaction diagram results on 3CLpro (Fig. 3), PLpro (Fig. 4), and RDRP (Fig. 5) were shown for a more in-depth understanding of the intermo-

lecular interactions between baicalin and 3CLpro, PLpro, and RDRP of SARS-CoV-2. According to bond interaction statistics (Table 2), baicalin formed multiple bond interaction with residues HIS41, CYS44, LEU141, ASN142, GLY143, CYS145, HIS163, GLU166, and MET165 of 3CLpro, and the interactions included 11 hydrogen bonds and 4 hydrophobic interactions. In addition, baicalin formed multiple bond interactions with residues CYS111, LEU162, GLY163, TYR264, and GLY271 of PLpro, with 9 hydrogen bonds and 1 hydrophobic interaction. For RDRP, baicalin also formed bond interactions with residues LYS545, Arg555, ASN691, and ASP760 of RDRP, and it consisted of

Fig. 3. Molecular docking model of baicalin binding to 3CLpro. The left panel shows the 3D ligand interaction model of selective binding sites between baicalin and 3CLpro using Discovery Studio 2021. The right panel shows the 2D ligand interaction diagram be-

tween baicalin and 3CLpro. Different bond interaction forces are illustrated with different colors as indicated in the figure. 3D, 3-dimensional; 2D, 2-dimensional; 3CLpro, 3-chymotrypsin-like cysteine protease.

11 hydrogen bonds and 2 hydrophobic interactions. In comparison among these docking patterns, the intermolecular interactions of ritonavir, lopinavir, or baicalin with 3CLpro showed that all 3 compounds shared the same binding pocket, and the baicalin-3CLpro interaction consists of more residue involvements than the others (Fig. 3, 6). In addition, among the 3 drug targets, baicalin showed the highest fitting value but the lowest docking score to 3CLpro, followed by PLpro and RDRP (Table 1).

Inhibition of 3CLpro and PLpro Protease Activities by Baicalin

Since baicalin exhibited high binding affinity to 3CLpro and PLpro, we next determined whether baicalin could inhibit the protease activities of 3CLpro and PLpro. The *in vitro* protease activity assay demonstrated that the activity of 3CLpro was effectively attenuated by baicalin at 50, 100, and 200 μM in a concentration-dependent manner (Fig. 7). In addition, baicalin also exerted significant inhibition on PLpro activity at 12.5, 25, 50, 100, and 200 μM in a dose-dependent manner (Fig. 8). Our data indicated that the activity of PLpro protease was more sensitive to baicalin treatment than that of 3CLpro. The IC_{50} values of

baicalin and positive controls (GC376 and HY-17542) on protease activities are presented in Table 3.

KEGG Pathway Analysis Result

The KEGG pathway analysis result showed the possible effects of baicalin on certain targets in the view of relevant cellular signaling pathway. In the “Coronavirus disease – COVID-19” pathway (shown in Fig. 9), the targets detected by the KEGG mapper tool were mitogen-activated protein kinase (MAPK), spleen-associated tyrosine kinase (SYK), and phosphatidylinositol-3-kinase (PI3K), involved in the IgG-induced signal cascade. Besides, interleukin-1 receptor-associated kinase is also found as possible target that involved in the toll-like receptor 2/4 signaling pathway. The MAPK pathway is also analyzed in more detail (shown in Fig. 10), which showed the involvements of interleukin-1 receptor-associated kinase 1/4 and the phosphorylation cascade of p38 and MAPK, following the signal transduction after IL-1 bound to IL-1R. In the “chemokine signaling pathway” (shown in Fig. 11), targets detected by the KEGG mapper tool were PI3K and GSK3 (glycogen synthase kinase 3) which involved both cytokine production and cell survival.

Fig. 4. Molecular docking model of baicalin binding to PLpro. The left panel shows the 3D ligand interaction model of selective binding sites between baicalin and PLpro using Discovery Studio 2021. The right panel shows the 2D ligand interaction diagram between

baicalin and PLpro. Different bond interaction forces are illustrated with different colors as indicated in the figure. 3D, 3-dimensional; 2D, 2-dimensional; PLpro, papain-like protease.

Fig. 5. Molecular docking model of baicalin binding to RDRP. The left panel shows the 3D ligand interaction model of selective binding sites between baicalin and RDRP using Discovery Studio 2021. The right panel shows the 2D ligand interaction diagram between

baicalin and RDRP. Different bond interaction forces are illustrated with different colors as indicated in the figure. 3D, 3-dimensional; 2D, 2-dimensional; RDRP, RNA-dependent RNA polymerase.

Target of 3-chymotrypsin-like cysteine protease (3CLpro)	Interaction Residues
Baicalin	HIS41 、 CYS44 、 LEU141 、 ASN142 、 GLY143 、 CYS145 、 HIS163 、 GLU166 、 MET165
Ritonavir	MET49, ASN142, CYS145, GLU166, PRO168, GLN189, THR190
Lopinavir	THR26 、 HIS41 、 MET49 、 ASN142 、 CYS145 、 GLU166 、 GLN189

Fig. 6. Molecular docking model of ritonavir and lopinavir binding to 3CLpro. The 3D ligand interaction models at the binding site, between ritonavir (upper left) and lopinavir (upper right) on 3CLpro using Discovery Studio 2021. Lower panel shows statistics of

interaction residues between ligands (baicalin, ritonavir, and lopinavir) in the binding site of 3CLpro. 3D, 3-dimensional; 3CLpro, 3-chymotrypsin-like cysteine protease.

Table 2. The interaction statistics between the baicalin and with 3CLpro, PLpro, and RDRP of SARS-CoV-2

Target	H-bonds, <i>n</i>	Hydro-phobics, <i>n</i>	Interaction residues
3CLpro	11	4	HIS41, CYS44, LEU141, ASN142, GLY143, CYS145, HIS163, GLU166, and MET165
PLpro	9	1	LEU162, GLY163, GLY271, TYR264, and CYS111
RDRP	11	2	ASN691, LYS545, ASP760, and ARG555

3CLpro, 3-chymotrypsin-like cysteine protease; PLpro, papain-like protease; RDRP, RNA-dependent RNA polymerase.

Discussion

The 3 enzymes taken into this study, 3CLpro, PLpro, and RDRP, are characterized as highly conserved structures [35] as there is no report about the mutation in new

emerging variants of SARS-CoV-2. Therefore, developing COVID-19 therapeutics targeting these enzymes is taking interest from laboratories. Approved antiviral drugs, such as lopinavir and ritonavir, showed consistency of in silico and in vitro data for the inhibitory effect on 3CLpro [36].

Fig. 7. Inhibitory effects of baicalin on the 3CLpro activity. The enzymatic and inhibition activity assay showed that baicalin inhibited 3CLpro activity at the concentrations of 12.5 μM , 25 μM , 50 μM , 100 μM , and 200 μM in a concentration-dependent manner. All data are shown as mean $\pm$ SD from 3 independent experiments. *** p < 0.001 versus untreated control. 3CLpro, 3-chymotrypsin-like cysteine protease.

Fig. 8. Inhibitory effects of baicalin on PLpro activity. The enzymatic and inhibition activity assay showed that baicalin inhibited PLpro activity at the concentrations of 12.5 μM , 25 μM , 50 μM , 100 μM , and 200 μM in a concentration-dependent manner. All data are shown as mean $\pm$ SD from 3 independent experiments. *** p < 0.001 versus untreated control. PLpro, papain-like protease.

Here, we examined the binding affinity of baicalin on the proteases (3CLpro and PLpro) and RDRP of SARS-CoV-2 by pharmacophore fitting and molecular docking. The pharmacophore mapping result showed that baicalin may be fit within the binding site of 3CLpro (Table 1). In addition, the molecular docking results are explicable with the formation of multiple bonds between ligand (baicalin) and the side chain residues at the binding cavity (Table 2). It also suggested that baicalin could interact with 3CLpro at the binding site to form a ligand-protein complex. The binding site of baicalin on the proteases (shown in Fig. 3–5) is similar to that of suggested inhibitors from previous

Table 3. The half maximal inhibitory concentration (IC_{50}) of baicalin, GC376, and HY-17542 on protease activities

Compound	3CLpro	PLpro
Baicalin, μM	>200	177.6
GC376 (positive control of 3CLpro), μM	0.0087	ND
HY-17542 (positive control of PLpro), μM	ND	1.73

Protease activities were monitored as a time-course measurement of the increase in fluorescence signal from fluorescently labeled peptide substrate, and the initial linear portion of slope (signal/min) was analyzed. ND indicates compound not tested against enzyme. 3CLpro, 3-chymotrypsin-like cysteine protease; PLpro, papain-like protease.

Fig. 9. Targets of baicalin (annotated with green color) in the pathway “Coronavirus disease – COVID-19 – *Homo sapiens* (human).” KEGG pathway ID: hsa05171. KEGG copyright permission ID: 210346.

Fig. 10. Targets of baicalin (annotated with green color) in the pathway “MAPK signaling pathway – *Homo sapiens* (human).” KEGG pathway ID: hsa04010. KEGG copyright permission ID: 210346.

studies [7, 8, 37]. As reported by previous studies, these binding modes may confer an inhibitory effect by occupying catalytic cavity of enzymes [35]. However, with a low LigScore value, the intermolecular affinity of baicalin to 3CLpro was predicted lower than that of the clinical antiviral drugs ritonavir and lopinavir as previously defined for the algorithm of scoring function [38]. Consequently, the stability of the baicalin-3CLpro complex may not stable due to attributes of the van der Waals interaction, the polar attraction, and the desolvation penalty [38].

A study on baicalin and its aglycon, baicalein, showed that both compounds exert in vitro inhibitory effects on the RDRP of SARS-CoV-2; however, baicalin exhibited low potency than baicalein [39]. In this study, the pharmacophore fitting value of baicalin on RDRP received lower value than that of the other targets and below 0.5

(Table 1). Moreover, both the pharmacophore assay result and docking score of baicalin were found lower than those of remdesivir. Furthermore, the interaction statistics between baicalin and RDRP displayed only with 4 residues involved (Table 2), lower than that of 3CLpro and PLpro. These results suggested that the intermolecular interactions between baicalin and RDRP may not strong enough to establish stable binding and showed consistency with the previous study [39]. Therefore, we only selected 3CLpro and PLpro for in vitro experiments.

In vitro experiments were conducted for investigation of enzymatic inhibition effects on selected target proteins. We found that baicalin can inhibit the enzymatic activity of 3CLpro and PLpro (shown in Fig. 7, 8) as suggested by in silico data. However, the inhibitory effect of baicalin on 3CLpro ($IC_{50} > 200 \mu M$) is relative weaker than that on

Fig. 11. Targets of baicalin (annotated with green color) in the pathway “Chemokine signaling pathway – *Homo sapiens* (human).” KEGG pathway ID: hsa04062. KEGG copyright permission ID: 210346.

PLpro ($IC_{50} = 178 \mu M$). Previous studies using different in vitro methods showed that baicalin has a good inhibitory effect on 3CLpro [7, 20]. However, to the best of our knowledge, studies investigating the inhibitory effect of baicalin on PLpro have not been carried out. Therefore, our results may contribute as a reference when evaluating baicalin as an inhibitor of SARS-CoV-2 protease in future studies.

In addition to the investigation of the inhibitory effect on viral replication, we sought to uncover the possible effects of baicalin on the host cell. We investigated the possible targets of baicalin in human cells by a pharmacophore-based screening. Our results (shown in Table 4) revealed a set of target genes which were regulated following baicalin treatment. This result is consistent with previous reports that baicalin has a broad spectrum of biological effects [13]. Among those human targets, many of them are enzymes like oxidoreductases or transferases that partici-

pate in cellular oxidative activities. The finding is in accordance with the previous reported anti-oxidative activities of baicalin [40]. A previous review also indicated that flavonoids including baicalin possibly inhibit SARS-CoV-2 due to their antioxidant and antiviral functions [21]. Furthermore, the literature indicated that lowering oxidative stress may reduce the risk of complications in COVID-19 that associated with the development of a CS [41].

A recent study on 5 flavones of SB using the structural biology approach, revealed dual function of baicalin, including inhibitory effect against enzymatic activity of SARS-CoV-2 3CLpro and protective effect against respiratory damage [42]. In this study, pathway analyses were carried out in order to construct a better insight of potential baicalin-induced effects on important targets that may protect the cell against cytokine-induced inflammation. “Coronavirus disease – COVID-19 pathway” and “MAPK

Table 4. The potential human targets screening results of baicalin by pharmacophore analysis

Pharmacophore ID	Fit value	Gene name	KEGG ID	Target class	Class	Function
3hcn	0.93	HEMH_HUMAN	K01772	Enzymes	Lyases	Sole sub-subclass for lyases that do not belong in the other subclasses
2xxz	0.91	KDM6B_HUMAN	K11448	Enzymes	Oxidoreductases	Acting on paired donors, with O ₂ as the oxidant and incorporation or reduction of oxygen
3d9z	0.87	CAH2_HUMAN	K01672	Enzymes	Lyases	Carbonate dehydratase
1uu3	0.85	PDPK1_HUMAN	K06276	Enzymes	Transferases	Protein-serine-threonine kinases
2w0x	0.84	HIF1N_HUMAN	K00476	Enzymes	Oxidoreductases	Acting on paired donors, with O ₂ as the oxidant and incorporation or reduction of oxygen. The oxygen incorporated need not be derived from O ₂
1w0h	0.83	ERI1_HUMAN	Not found	Others	Others	Others
3iai	0.82	CAH9_HUMAN	K01672	Enzymes	Lyases	Carbonate dehydratase
2ivs	0.81	RET_HUMAN	K05126	Cytokine receptors	Receptor tyrosine kinase	RTK class XIV (RET receptor family)
2va6	0.81	BACE1_HUMAN	K04521	Enzymes	Hydrolases	Acting on peptide bonds (peptidases)
2w4o	0.80	KCC4_HUMAN	K05869	Enzymes	Transferases	Ca ²⁺ -calmodulin-dependent protein kinase
2xht	0.80	HS90A_HUMAN	K04079	Proteasome	Eukaryotic proteasome	HSP90A; molecular chaperone; assembling factors
3csj	0.79	GSTP1_HUMAN	K00799	Enzymes	Transferases	Glutathione transferase; transferring alkyl or aryl groups, other than methyl groups
1q5k	0.79	GSK3B_HUMAN	K03083	Enzymes	Transferases	Tau-protein kinase; transferring phosphorus-containing groups
3ij8	0.79	AMYP_HUMAN	K01176	Enzymes	Hydrolases	Alpha-amylase
2g2f	0.78	ABL1_HUMAN	K06619	Protein kinases	Tyrosine protein kinases	Abl family
2v4l	0.78	PK3CG_HUMAN	K00922	Enzymes	Transferases	Phosphatidylinositol-4,5-bisphosphate 3-kinase
2wms	0.77	CHK1_HUMAN	K02216	Enzymes	Transferases	Nonspecific serine-threonine protein kinase
1e1x	0.77	CDK2_HUMAN	K02206	Enzymes	Transferases	Cyclin-dependent kinase
1u59	0.77	ZAP70_HUMAN	K07360	Cellular antigens	Non-CD molecules	ZAP70; zeta-chain (TCR) associated protein kinase, 70 kDa
1xbc	0.76	KSVK_HUMAN	K05855	Enzymes	Transferases	Nonspecific protein-tyrosine kinase
2w8r	0.74	SSDH_HUMAN	K00139	Enzymes	Oxidoreductases	Succinate-semialdehyde dehydrogenase (NAD+)
2ybu	0.73	CHIA_HUMAN	K01183	Enzymes	Hydrolases	Glycosylases; chitinase
2our	0.73	PDE10_HUMAN	K01120	Enzymes	Hydrolases	3',5'-cyclic-nucleotide phosphodiesterase
3dzh	0.73	CD38_HUMAN	K01242	Enzymes	Hydrolases	Glycosylases; NAD + nucleosidase
3ddu	0.72	PPCE_HUMAN	K01322	Enzymes	Hydrolases	Acting on peptide bonds (peptidases)

Table 4 (continued)

Pharmacophore ID	Fit value	Gene name	KEGG ID	Target class	Class	Function
2oic	0.71	IRAK4_HUMAN	K04733	Protein kinases	Serine-threonine protein kinases – TKL group	Serine-threonine protein kinases
1h69	0.71	NQO1_HUMAN	K00355	Enzymes	Oxidoreductases	NAD (P)H dehydrogenase
3iad	0.71	PDE4D_HUMAN	K01120	Enzymes	Hydrolases	3',5'-cyclic-nucleotide phosphodiesterase
3flw	0.71	MK14_HUMAN	K04441	Enzymes	Transferases	MAPK
3fxw	0.70	MAPK3_HUMAN	K04444	Enzymes	Transferases	Serine-threonine protein kinases
1zkk	0.70	SETD8_HUMAN	K11428	Enzymes	Transferases	Histone-lysine N-methyltransferase
3bhh	0.69	KCC2B_HUMAN	K04515	Enzymes	Transferases	Ca2+-calmodulin-dependent protein kinase
2ydo	0.67	AA2AR_HUMAN	K04266	G protein-coupled receptors	Class A. Rhodopsin family	Adenosine receptor A2a; base and nucleoside
3hmi	0.67	ABL2_HUMAN	K08887	Enzymes	Transferases	Protein-tyrosine kinase
2rdt	0.66	HAOX1_HUMAN	K11517	Enzymes	Oxidoreductases	(S)-2-hydroxy acid oxidase
1isj	0.66	BST1_HUMAN	K01242	Enzymes	Hydrolases	Glycosylases; NAD + nucleosidase
1b3d	0.66	MMP3_HUMAN	K01394	Enzymes	Hydrolases	Acting on peptide bonds (peptidases); stromelysin 1
2wtd	0.65	CHK2_HUMAN	K06641	DNA repair and recombination proteins	Eukaryotic type	CHK2; serine-threonine-protein kinase Chk2
1byg	0.65	CSK_HUMAN	K05728	Enzymes	Transferases	Protein-tyrosine kinase
3frg	0.65	PDE4B_HUMAN	K01120	Enzymes	Hydrolases	3',5'-cyclic-nucleotide phosphodiesterase
2igq	0.64	EHMT1_HUMAN	K11420	Chromosome	Eukaryotic type	HKMTs
3kbz	0.64	F16P1_HUMAN	K03841	Enzymes	Hydrolases	Fructose-bisphosphatase
2vwy	0.64	EPHB4_HUMAN	K05113	Enzymes	Transferases	Receptor protein-tyrosine kinase
3bhm	0.64	CBR1_HUMAN	K00079	Enzymes	Oxidoreductases	Carbonyl reductase (NADPH)
2ikg	0.61	ALDR_HUMAN	K00011	Enzymes	Oxidoreductases	Aldehyde reductase
2i4i	0.61	DDX3X_HUMAN	K11594	Enzymes	Hydrolases	RNA helicase
MAPK, mitogen-activated protein kinase; HKMTs, histone lysine methyltransferases.						

signaling pathways” (shown in Fig. 9, 10) indicated involvements of MAPK, SYK, and PI3K as targets of baicalin. This result is in accordance with previously reported studies that baicalin inhibits p38 MAPK, and this mechanism may be responsible for its anti-inflammation effect [23, 25, 43, 44]. MAPK is activated under the stress of cytokine; therefore, inhibiting MAPK is a promising approach for hyper-inflammatory disease, such as COVID-19 [45]. Last, analysis on the pathway of “chemokine signaling” revealed involvements of PI3K and GSK3 as targets of baicalin. These 2 targets serve in the signal cascade, induced by chemokine after interacting directly with its specific receptor on the surface of the cell. The chemokine, as a pro-inflammatory factor, triggers signal to activate NF- κ B and eventually promotes cytokine production. The produced cytokines can be released and cause further cycles of cytokine amplification that is harmful in acute inflammation condition, such as in COVID-19. According to previous reports, baicalin regulates the PI3K/AKT signal [24] and NF- κ B [23, 43], and these activities may be responsible for baicalin-induced anti-inflammatory effect [16, 23, 43]. Our analysis and the supportive data from the literature suggested that baicalin may protect the cell from pro-inflammatory factors, such as cytokine and chemokine, through disrupting several inflammation-associated signaling pathways inside the cell. This result suggests a potential of baicalin to act as an anti-inflammatory compound that may alleviate cytokine-induced symptoms.

Our study has a number of limitations. All *in silico* results require further experimental verification. Although the *in silico* data of baicalin suggested a better fitting score on 3CLpro than PLpro, the relative difference between IC₅₀ values however showed opposite difference. Admittedly, molecular docking may not reflex the actual ligand-protein interactions. However, docking patterns of baicalin on proteases are required for further structural based drug design, for example, baicalin derivatives to improve the specificity and efficacy on targets. Additionally, the effect on targets found in pathway analysis results, such as MAPK, SYK, PI3K, and GSK3, are needed to be further investigated. Furthermore, the metabolic profile of baicalin should be also taken into account in subsequent studies.

Conclusion

Our study indicated that baicalin, a natural compound that has been used in traditional Chinese medicine with minimal side effects, has a potential therapeutic effect against SARS-CoV-2 infection. Baicalin exhibits a signifi-

cant inhibitory effect on PLpro and 3CLpro of SARS-CoV-2, possibly by direct binding on the catalytic site of these enzymes. Moreover, baicalin has potential on manipulating inflammation-related pathways that possibly diminishing the “cytokine storm” syndrome which may occur in severe cases of COVID-19. Our findings suggested that continuous research is needed to develop baicalin as a supportive treatment therapeutic for COVID-19.

Acknowledgments

We thank Kuan-Wen Chen and Tzu-Mao Hung in GGA Corporation, Molecular Science Center (Taiwan) for performing the molecular docking to 3CLpro, PLpro, and RDRP.

Statement of Ethics

The paper is exempt from Ethics Committee approval since this study uses *in silico* and *in vitro* approaches, and no human or animal testing has been conducted.

Conflict of Interest Statement

The authors declare no conflict of interest.

Funding Sources

Funding for this study was provided in part by research grants from the China Medical University Hospital, Taichung, Taiwan awarded to Dr. J.-S. Yang (Grant No: DMR-110-136), to Y.-M. Hsu (Grant No: CMU106-S-13) and a grant from the Ministry of Science and Technology, Taiwan awarded, to Dr. J.-S. Yang (MOST 109-2320-B-039-041).

Author Contributions

C. Lin, H.-A. Ha, F.-J. Tsai, and J.-S. Yang were involved in the design of the study. Y.-M. Hsu, T.-J. Ho, G.-K. Wang, and Y.-J. Chiu performed the experiments. C. Lin, H.-A. Ha, Y.-J. Chiu, and J.-S. Yang drafted the manuscript. C. Lin, F.-J. Tsai, H.-A. Ha, and J.-S. Yang were involved in the revising and editing of the manuscript. All the authors have read and approved the final manuscript.

Data Availability Statement

All data generated or analyzed during this study are included in this article and its online supplementary material file. Further inquiries can be directed to the corresponding author.

References

- Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. *Int J Surg*. 2020 Jun; 78:185–93.
- Ali I, Alharbi OML. COVID-19: disease, management, treatment, and social impact. *Sci Total Environ*. 2020 Aug 1;728:138861.
- Alaran AJ, Adebisi YA, Badmos A, Khalid-Salako F, Gaya SK, Ilesanmi EB, et al. Uneven power dynamics must be levelled in COVID-19 vaccines access and distribution. *Public Health Pract*. 2021;2: 100096.
- Wibawa T. COVID-19 vaccine research and development: ethical issues. *Trop Med Int Health*. 2021;26(1):14–9.
- Madas BG, Fűri P, Farkas Á, Nagy A, Czitrovsky A, Balászhy I, et al. Deposition distribution of the new coronavirus (SARS-CoV-2) in the human airways upon exposure to cough-generated droplets and aerosol particles. *Sci Rep*. 2020;10(1): 22430.
- Tsai SC, Lu CC, Bau DT, Chiu YJ, Yen YT, Hsu YM, et al. Approaches towards fighting the COVID-19 pandemic (Review). *Int J Mol Med*. 2021 Jan;47(1):3–22.
- Jo S, Kim S, Kim DY, Kim MS, Shin DH. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. *J Enzyme Inhib Med Chem*. 2020;35(1):1539–44.
- Rehman M, AlAjmi MF, Hussain A. Natural compounds as inhibitors of SARS-CoV-2 main protease (3CLpro): a molecular docking and simulation approach to combat COVID-19. *Curr Pharma Des*. 2020.
- Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B*. 2020;10(5):766–88.
- Mishra KP, Singh AK, Singh SB. Hyperinflammation and immune response generation in COVID-19. *Neuroimmunomodulation*. 2020;27(2):80–6.
- Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVID-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents*. 2020 March;34(2):327–31.
- Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. *Clin Immunol*. 2020 Jun; 215:108448.
- Huang T, Liu Y, Zhang C. Pharmacokinetics and bioavailability enhancement of baicalin: a review. *Eur J Drug Metab Pharmacokinet*. 2019 Apr;44(2):159–68.
- Zhang QH, Tan L, Gou Q, Zhou LD, Wang CZ, Yuan CS. 6,8-di-C-glycosyl flavones with β -furanosarabinose from scutellaria baicalensis and their anti-inflammatory activities. *Nat Prod Res*. 2019 May;33(9):1243–50.
- Ming J, Zhuoneng L, Guangxun Z. Protective role of flavonoid baicalin from scutellaria baicalensis in periodontal disease pathogenesis: a literature review. *Complement Ther Med*. 2018 Jun;38:11–8.
- Liao H, Ye J, Gao L, Liu Y. The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: a comprehensive review. *Biomed Pharmacother*. 2021;133:110917.
- Leonova GN, Shutikova AL, Lubova VA, Maistrovskaya OS. Inhibitory activity of scutellaria baicalensis flavonoids against tick-borne encephalitis virus. *Bull Exp Biol Med*. 2020 Mar;168(5):665–8.
- Zandi K, Lim TH, Rahim NA, Shu MH, Teoh BT, Sam SS, et al. Extract of Scutellaria baicalensis inhibits dengue virus replication. *BMC Complement Altern Med*. 2013 Apr 29; 13:91.
- Chandra A, Chaudhary M, Qamar I, Singh N, Nain V. In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase. *J Biomol Struct Dyn*. 2021 Feb 15:1–11.
- Liu H, Ye F, Sun Q, Liang H, Li C, Li S, et al. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro. *J Enzyme Inhib Med Chem*. 2021;36(1):497–503.
- Russo M, Moccia S, Spagnuolo C, Tedesco I, Russo GL. Roles of flavonoids against coronavirus infection. *Chem Biol Interact*. 2020 Sep 1;328:109211.
- Zhong LLD, Lam WC, Yang W, Chan KW, Sze SCW, Miao J, et al. Potential targets for treatment of coronavirus disease 2019 (COVID-19): a review of Qing-Fei-Pai-Du-Tang and its major herbs. *Am J Chin Med*. 2020; 48(5):1051–71.
- Fang F, Xie Z, Quan J, Wei X, Wang L, Yang L. Baicalin suppresses Propionibacterium acnes-induced skin inflammation by down-regulating the NF- κ B/MAPK signaling pathway and inhibiting activation of NLRP3 inflammasome. *Braz J Med Biol Res*. 2020;53: e9949.
- Zhu L, Shen H, Gu PQ, Liu YJ, Zhang L, Cheng JF. Baicalin alleviates TNBS-induced colitis by inhibiting PI3K/AKT pathway activation. *Exp Ther Med*. 2020;20(1): 581–90.
- Fu S, Zhao W, Xiong C, Guo L, Guo J, Qiu Y, et al. Baicalin modulates apoptosis via RAGE, MAPK, and AP-1 in vascular endothelial cells during Haemophilus parasuis invasion. *Innate Immun*. 2019;25(7):420–32.
- Curtis JR, Owensby JK, Xie F. Comparative safety of flavocoxid versus prescription NSAIDs among osteoarthritis patients. *Osteoarthritis Cartilage*. 2020 Jul;28(7):917–23.
- Boozari M, Hosseinzadeh H. Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies. *Phytother Res*. 2021 Feb; 35(2):864–76.
- Chen KH, Wang SF, Wang SY, Yang YP, Wang ML, Chiou SH, et al. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019. *J Chin Med Assoc*. 2019;83(9): 817–21.
- Berman HM, Bhat TN, Bourne PE, Feng Z, Gilliland G, Weissig H, et al. The protein data bank and the challenge of structural genomics. *Nat Struct Biol*. 2000;7(1):957–9.
- Rut W, Lv Z, Zmudzinski M, Patchett S, Nayak D, Snipas SJ, et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. *Sci Adv*. 2020 Oct;6(42):4596.
- Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science*. 2020 Jun 26;368(6498):1499–504.
- Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature*. 2020; 582(7811):289–93.
- Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res*. 2017 Jan 4;45(D1):D353–d61.
- Sanders JM, Monogue ML, Jodkowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. *JAMA*. 2020 May 12;323(18):1824–36.
- Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B*. 2020 May;10(5):766–88.
- Zhang L, Liu J, Cao R, Xu M, Wu Y, Shang W, et al. Comparative antiviral efficacy of viral protease inhibitors against the novel SARS-CoV-2 in vitro. *Virol Sin*. 2020;35(6):776–84.
- Rajpoot S, Alagumuthu M, Baig MS. Dual targeting of 3CLpro and PLpro of SARS-CoV-2: a novel structure-based design approach to treat COVID-19. *Curr Res Struct Biol*. 2021; 3:9–18.
- Krammer A, Kirchhoff PD, Jiang X, Venkatachalam CM, Waldman M. LigScore: a novel scoring function for predicting binding affinities. *J Mol Graph Model*. 2005 Apr; 23(5):395–407.
- Zandi K, Musall K, Oo A, Cao D, Liang B, Hassandarvish P, et al. Baicalein and baicalin inhibit SARS-CoV-2 RNA-dependent-RNA polymerase. *Microorganisms*. 2021;9(5):893.

- 40 Wu Y, Wang F, Fan L, Zhang W, Wang T, Du Y, et al. Baicalin alleviates atherosclerosis by relieving oxidative stress and inflammatory responses via inactivating the NF- κ B and p38 MAPK signaling pathways. *Biomed Pharmacother*. 2018 Jan;97:1673–9.
- 41 Chernyak BV, Popova EN, Prikhodko AS, Grebenchikov OA, Zinovkina LA, Zinovkin RA. COVID-19 and oxidative stress. *Biochemistry*. 2020;85(12):1543–53.
- 42 Udrea A-M, Mernea M, Buiu C, Avram S. Scutellaria baicalensis flavones as potent drugs against acute respiratory injury during SARS-CoV-2 infection: structural biology approaches. *Processes*. 2020;8(11):1468.
- 43 Pu WL, Bai RY, Zhou K, Peng YF, Zhang MY, Hottiger MO, et al. Baicalein attenuates pancreatic inflammatory injury through regulating MAPK, STAT 3 and NF- κ B activation. *Int Immunopharmacol*. 2019;72:204–10.
- 44 Zhang L, Wang X, Wang R, Zheng X, Li N, Li H, et al. Baicalin potentiates TRAIL-induced apoptosis through p38 MAPK activation and intracellular reactive oxygen species production. *Mol Med Rep*. 2017;16(6):8549–55.
- 45 Grimes JM, Grimes KV. p38 MAPK inhibition: a promising therapeutic approach for COVID-19. *J Mol Cell Cardiol*. 2020;144:63–5.